262 related articles for article (PubMed ID: 21872901)
21. The age of protein kinases.
Dissmeyer N; Schnittger A
Methods Mol Biol; 2011; 779():7-52. PubMed ID: 21837559
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases.
Beeton CA; Chance EM; Foukas LC; Shepherd PR
Biochem J; 2000 Sep; 350 Pt 2(Pt 2):353-9. PubMed ID: 10947948
[TBL] [Abstract][Full Text] [Related]
23. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
24. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
Bamborough P; Drewry D; Harper G; Smith GK; Schneider K
J Med Chem; 2008 Dec; 51(24):7898-914. PubMed ID: 19035792
[TBL] [Abstract][Full Text] [Related]
25. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
26. [Mechanism of action of cAMP-dependent protein kinase. V. Free energy spectra].
Kochetkov SN; Abduragimov AR; Gabibov AG; Severin ES
Mol Biol (Mosk); 1985; 19(6):1562-8. PubMed ID: 4079933
[TBL] [Abstract][Full Text] [Related]
27. Drug discovery and the human kinome: recent trends.
Eglen R; Reisine T
Pharmacol Ther; 2011 May; 130(2):144-56. PubMed ID: 21256157
[TBL] [Abstract][Full Text] [Related]
28. Sequence-based protein kinase inhibition: applications for drug development.
Wexler I; Niv M; Reuveni H
Biotechniques; 2005 Oct; 39(10 Suppl):S575-6. PubMed ID: 18957040
[No Abstract] [Full Text] [Related]
29. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors.
Akritopoulou-Zanze I; Hajduk PJ
Drug Discov Today; 2009 Mar; 14(5-6):291-7. PubMed ID: 19121409
[TBL] [Abstract][Full Text] [Related]
30. The identification of new protein kinase inhibitors as targets in modern drug discovery.
Akritopoulou-Zanze I
IDrugs; 2006 Jul; 9(7):481-7. PubMed ID: 16821161
[TBL] [Abstract][Full Text] [Related]
31. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
Klüter S; Simard JR; Rode HB; Grütter C; Pawar V; Raaijmakers HC; Barf TA; Rabiller M; van Otterlo WA; Rauh D
Chembiochem; 2010 Dec; 11(18):2557-66. PubMed ID: 21080395
[TBL] [Abstract][Full Text] [Related]
32. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
33. Protein kinases: From targets to anti-cancer drugs.
Cruzalegui F
Ann Pharm Fr; 2010 Jul; 68(4):254-9. PubMed ID: 20637357
[TBL] [Abstract][Full Text] [Related]
34. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors.
Jahnke W; Blommers MJ; Fernández C; Zwingelstein C; Amstutz R
Chembiochem; 2005 Sep; 6(9):1607-10. PubMed ID: 16028302
[No Abstract] [Full Text] [Related]
35. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
Hantschel O
ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
[TBL] [Abstract][Full Text] [Related]
36. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
Sheinerman FB; Giraud E; Laoui A
J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
[TBL] [Abstract][Full Text] [Related]
37. High-throughput kinase profiling as a platform for drug discovery.
Goldstein DM; Gray NS; Zarrinkar PP
Nat Rev Drug Discov; 2008 May; 7(5):391-7. PubMed ID: 18404149
[TBL] [Abstract][Full Text] [Related]
38. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
Duncan JS; Haystead TA; Litchfield DW
Methods Mol Biol; 2012; 795():119-34. PubMed ID: 21960219
[TBL] [Abstract][Full Text] [Related]
39. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
[TBL] [Abstract][Full Text] [Related]
40. Quantitative proteomics of kinase inhibitor targets and mechanisms.
Daub H
ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
